
Please try another search
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bispecifics, ADCs, CAR-T, and V-body-oligonucleotide conjugates. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Lorenzo Galluzzi | - | 2021 | Member of Scientific Advisory Committee |
Gilles Favre | - | 2021 | Member of Scientific Advisory Committee |
Gilbert Chu | - | 2021 | Member of Scientific Advisory Committee |
Bryan Giraudo | 50 | 2021 | Independent Director |
Julien Miara | 42 | 2020 | CEO & Chairman |
Ruth Plummer | - | 2021 | Member of Scientific Advisory Committee |
Nicolas Trebouta | 62 | 2011 | Representative Director |
Caroline Robert | - | 2021 | Member of Scientific Advisory Committee |
Jacques Mallet | 65 | 2021 | Independent Director |
Antoine Barouky | - | 2025 | Deputy CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review